Publicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (11)

2021

  1. SEOM Clinical Guideline of management of soft-tissue sarcoma (2020)

    Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 922-930

2018

  1. Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study

    Investigational New Drugs, Vol. 36, Núm. 3, pp. 468-475

2016

  1. Brain metastases (BM) in colorectal cancer (CRC): Prognostic factors and survival analysis

    Annals of Oncology, Vol. 27, pp. vi195

  2. Genetic variations in the VEGF pathway as prognostic factors in stages II and III colon cancer

    Annals of Oncology, Vol. 27, pp. vi30

2012

  1. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: A phase II study evaluating co-treatment with dexamethasone

    Investigational New Drugs, Vol. 30, Núm. 2, pp. 729-740

2010

  1. Advanced ovarian cancer: Phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel

    Journal of the National Cancer Institute, Vol. 102, Núm. 20, pp. 1547-1556

2005

  1. Phase II clinical trial with pegylated liposomal doxorubicin (CAELYX®/Doxil®) and quality of life evaluation (EORTC QLQ-C30) in adult patients with advanced soft tissue sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS)

    Sarcoma, Vol. 9, Núm. 3-4, pp. 127-132

2003

  1. Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain

    British Journal of Cancer, Vol. 89, Núm. 6, pp. 1002-1007

2000

  1. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer

    Clinical Cancer Research, Vol. 6, Núm. 6, pp. 2356-2362

1998

  1. Activity of doxorubicin after high-dose ifosfamide in adult patients with advanced soft tissue sarcoma: A study of the Spanish Group for Research on Sarcomas (GEIS)

    Annals of Oncology, Vol. 9, Núm. 7, pp. 783-785

  2. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS)

    Annals of Oncology, Vol. 9, Núm. 8, pp. 871-876